Michael Teifel
Vice President
Management
Nanothinx
Germany
Biography
Over the last 20 years, Dr. Teifel has gained wide-ranging experience in translating fundamental research into clinical development in various therapeutic areas, mainly in oncology and endocrinology. He is particularly experienced in the design and implementation of non-clinical development programs for small molecule drugs, targeted therapies, and biologics, as well as in the continued non-clinical evaluation of drug candidates supporting global registration. After receiving his Ph.D. in 1996 from the Technical University of Darmstadt, Dr. Teifel started his career at Roche Diagnostics in the area of drug delivery systems / non-viral gene therapy. In 1999, he co-founded Munich Biotech, before joining Aeterna Zentaris in 2004.
Research Interest
Oncology and Endocrinology
